Harbour BioMed is a global clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics in oncology and immunological disease areas to address unmet patient needs. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions....
Harbour BioMed is a global clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics in oncology and immunological disease areas to address unmet patient needs. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions. The Company’s proprietary antibody technology platform Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as a heavy chain only (HCAb) format.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.